Advanced Therapy Medicinal Products (ATMPs) face high adoption barriers and commercial risk because:
- There is a lack of long-term clinical data at launch to support value claims of sustainability of effect
- High manufacturing costs require high reimbursed prices to secure commercial viability
- Preparing healthcare system infrastructure for adoption is resource intensive
Our health economics and market access team can work with you to develop the health-economic strategy and models that are uniquely relevant to ATMPs and that will give your ATMP the best chance of success:
Shaping early development (pre-clinical stage)
Define parameters of commercial viability in terms of therapeutic positioning and thresholds of product performance and manufacturing costs; Inform clinical and manufacturing strategy accordingly.
Opportunity optimisation (pre-pivotal clinical trial stage)
Health economic analyses and key market access stakeholder engagement, define the interrelationship between value story, reimbursed price potential and corresponding evidence requirements; inform the evidence generation plan accordingly.
Address data uncertainty, healthcare system affordability, infrastructure and treatment pathway constraints; leverage Innovative reimbursement mechanisms and post-launch real world evidence collection.
Working on a cell or gene therapy innovation challenge?
Contact us today to find out how we can support you.